Human CTLA-4 Fc Recombinant Protein
442.99 €
In Stock
quantity
product details
Catalog number: 209 - 100-059S
Product Category: Business & Industrial > Science & Laboratory
Gentaur
Size: 50 µg
40-692
CTLA-4 Fc Recombinant Protein
CTLA-4 and CD28 are receptors of the immunoglobulin superfamily that are expressed, along with the transmembrane glycoproteins B7-1 and B7-2, by antigen-presenting cells, and with these ligands constitute crucial co-stimulatory pathways for T and B cell regulatory responses. It is through engagement with CD28 and CTLA-4 that the B7 family ligands B7-1 and B7-2 play principal roles in immunity by activating immune response and maintaining immune tolerance. Co-stimulatory signals generated by B7-1 and B7-2 interactions with CD28 serve to stimulate T cell activation and prevent anergy through the amplification of T cell receptor (TCR) signaling. In contrast, interactions of the ligands with CTLA-4 serves to maintain T cell homeostasis and self-tolerance through the disruption of stimulatory signaling from B7 isoform-bound CD28 complexes, and by inducing powerful inhibitory signals in T cells. CTLA-4, like B7-1, is only poorly expressed on resting dendritic cells; therefore, up-regulation of their interaction and resultant amplification and regulation of T cell activity at peripheral inflammation sites is considerably delayed upon immune activation. Conversely, B7-2 and CD28 are constitutively expressed by resting hematopoietic and T cells, respectively, and as a result are able to rapidly induce up-regulation upon immune activation, making them critical to the early co-stimulatory signaling of immune response. Unlike B7-1 and B7-2, the ligands PD-L1 (or B7-H1) and B7-H2, which also belong to the B7 family, have not been shown to influence immunity through interaction with CTLA-4. B7-H2 has been shown to have restricted interaction with CD28. The difference in expression of B7-1, B7-2 and B7-H2 may enable temporally and spatially-specific regulation of T cell response through non-competitive CD28 interaction. CHO cell-derived Recombinant Human CTLA-4 Fc is a glycosylated, disulfide-linked homodimer of 714 amino acid residues whose monomer consists of the 124-amino-acid length extracellular portion of CTLA-4 fused to the 231-amino-acid length Fc portion of human IgG1 by two glycines. The calculated molecular weight of Recombinant Human CTLA-4 Fc dimer is 78.7 kDa; however, due to glycosylation, the monomer and dimer migrate at apparent molecular weights of approximately 45–50 kDa and 80–90 kDa by SDS-PAGE analysis under reducing conditions.
602.62 €
100-059
Human CTLA-4 Fc Recombinant Protein
CTLA-4 and CD28 are receptors of the immunoglobulin superfamily that are expressed, along with the transmembrane glycoproteins B7-1 and B7-2, by antigen-presenting cells, and with these ligands constitute crucial co-stimulatory pathways for T and B cell regulatory responses. It is through engagement with CD28 and CTLA-4 that the B7 family ligands B7-1 and B7-2 play principal roles in immunity by activating immune response and maintaining immune tolerance. Co-stimulatory signals generated by B7-1 and B7-2 interactions with CD28 serve to stimulate T cell activation and prevent anergy through the amplification of T cell receptor (TCR) signaling. In contrast, interactions of the ligands with CTLA-4 serves to maintain T cell homeostasis and self-tolerance through the disruption of stimulatory signaling from B7 isoform-bound CD28 complexes, and by inducing powerful inhibitory signals in T cells. CTLA-4, like B7-1, is only poorly expressed on resting dendritic cells; therefore, up-regulation of their interaction and resultant amplification and regulation of T cell activity at peripheral inflammation sites is considerably delayed upon immune activation. Conversely, B7-2 and CD28 are constitutively expressed by resting hematopoietic and T cells, respectively, and as a result are able to rapidly induce up-regulation upon immune activation, making them critical to the early co-stimulatory signaling of immune response. Unlike B7-1 and B7-2, the ligands PD-L1 (or B7-H1) and B7-H2, which also belong to the B7 family, have not been shown to influence immunity through interaction with CTLA-4. B7-H2 has been shown to have restricted interaction with CD28. The difference in expression of B7-1, B7-2 and B7-H2 may enable temporally and spatially-specific regulation of T cell response through non-competitive CD28 interaction. Recombinant Human CTLA-4 Fc is a glycosylated, disulfide-linked homodimer of 714 amino acid residues whose monomer consists of the 124-amino-acid length extracellular portion of CTLA-4 fused to the 231-amino-acid length Fc portion of human IgG1 by two glycines. The calculated molecular weight of Recombinant Human CTLA-4 Fc dimer is 78.7 kDa; however, due to glycosylation, the monomer and dimer migrate at apparent molecular weights of approximately 45–50 kDa and 80–90 kDa by SDS-PAGE analysis under reducing conditions.
448.96 €
100-059S
Human CTLA-4 Fc Recombinant Protein
CTLA-4 and CD28 are receptors of the immunoglobulin superfamily that are expressed, along with the transmembrane glycoproteins B7-1 and B7-2, by antigen-presenting cells, and with these ligands constitute crucial co-stimulatory pathways for T and B cell regulatory responses. It is through engagement with CD28 and CTLA-4 that the B7 family ligands B7-1 and B7-2 play principal roles in immunity by activating immune response and maintaining immune tolerance. Co-stimulatory signals generated by B7-1 and B7-2 interactions with CD28 serve to stimulate T cell activation and prevent anergy through the amplification of T cell receptor (TCR) signaling. In contrast, interactions of the ligands with CTLA-4 serves to maintain T cell homeostasis and self-tolerance through the disruption of stimulatory signaling from B7 isoform-bound CD28 complexes, and by inducing powerful inhibitory signals in T cells. CTLA-4, like B7-1, is only poorly expressed on resting dendritic cells; therefore, up-regulation of their interaction and resultant amplification and regulation of T cell activity at peripheral inflammation sites is considerably delayed upon immune activation. Conversely, B7-2 and CD28 are constitutively expressed by resting hematopoietic and T cells, respectively, and as a result are able to rapidly induce up-regulation upon immune activation, making them critical to the early co-stimulatory signaling of immune response. Unlike B7-1 and B7-2, the ligands PD-L1 (or B7-H1) and B7-H2, which also belong to the B7 family, have not been shown to influence immunity through interaction with CTLA-4. B7-H2 has been shown to have restricted interaction with CD28. The difference in expression of B7-1, B7-2 and B7-H2 may enable temporally and spatially-specific regulation of T cell response through non-competitive CD28 interaction. Recombinant Human CTLA-4 Fc is a glycosylated, disulfide-linked homodimer of 714 amino acid residues whose monomer consists of the 124-amino-acid length extracellular portion of CTLA-4 fused to the 231-amino-acid length Fc portion of human IgG1 by two glycines. The calculated molecular weight of Recombinant Human CTLA-4 Fc dimer is 78.7 kDa; however, due to glycosylation, the monomer and dimer migrate at apparent molecular weights of approximately 45–50 kDa and 80–90 kDa by SDS-PAGE analysis under reducing conditions.
442.99 €
92-723
CTLA-4 Recombinant Protein
Mouse Cytotoxic Tlymphocyte 4(CTLA-4,CD152), is a type I transmembrane T cell inhibitory molecule. Within the ECD, Mouse CTLA-4 shares 68% aa sequence identity with human. CTLA4 is similar to the T cell costimulatory protein CD28 since both of the molecules bind to CD80 and CD86 on antigen-presenting cells. CTLA4 transmits an inhibitory signal to T cells, whereas CD28 transmits a stimulatory signal. Intracellular CTLA4 is also found inregulatory T cells and may play an important role in their functions. T cell activation through the T cell receptor and CD28 leads to increased expression of CTLA4. Genetic variations of CTLA4 have been associated with susceptibility to systemic lupus erythematosus(SLE), Gravesdisease(GRD), Celiac disease type3(CELIAC3) and Hepatitis B virus infection(HBVinfection).
745.78 €
96-215
CTLA 4 Recombinant Protein
CTLA-4 (Cytotoxic T-Lymphocyte Antigen 4) is also known as CD152 (Cluster of differentiation 152), is a protein receptor that downregulates the immune system. CTLA4 is a member of the immunoglobulin superfamily, which is expressed on the surface of Helper T cells and transmits an inhibitory signal to T cells. The protein contains an extracellular V domain, a transmembrane domain, and a cytoplasmic tail. Alternate splice variants, encoding different isoforms. CTLA4 is similar to the T-cell co-stimulatory protein, CD28, and both molecules bind to CD80 and CD86, also called B7-1 and B7-2 respectively, on antigen-presenting cells. CTLA4 transmits an inhibitory signal to T cells, whereas CD28 transmits a stimulatory signal. Intracellular CTLA4 is also found in regulatory T cells and may be important to their function. Fusion proteins of CTLA4 and antibodies (CTLA4-Ig) have been used in clinical trials for rheumatoid arthritis.
993.94 €
96-216
CTLA 4 Recombinant Protein
CTLA-4 (Cytotoxic T-Lymphocyte Antigen 4) is also known as CD152 (Cluster of differentiation 152), is a protein receptor that downregulates the immune system. CTLA4 is a member of the immunoglobulin superfamily, which is expressed on the surface of Helper T cells and transmits an inhibitory signal to T cells. The protein contains an extracellular V domain, a transmembrane domain, and a cytoplasmic tail. Alternate splice variants, encoding different isoforms. CTLA4 is similar to the T-cell co-stimulatory protein, CD28, and both molecules bind to CD80 and CD86, also called B7-1 and B7-2 respectively, on antigen-presenting cells. CTLA4 transmits an inhibitory signal to T cells, whereas CD28 transmits a stimulatory signal. Intracellular CTLA4 is also found in regulatory T cells and may be important to their function. Fusion proteins of CTLA4 and antibodies (CTLA4-Ig) have been used in clinical trials for rheumatoid arthritis.